These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25411637)

  • 1. Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials.
    Koenighofer M; Lion T; Bodenteich A; Prieschl-Grassauer E; Grassauer A; Unger H; Mueller CA; Fazekas T
    Multidiscip Respir Med; 2014; 9(1):57. PubMed ID: 25411637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial.
    Ludwig M; Enzenhofer E; Schneider S; Rauch M; Bodenteich A; Neumann K; Prieschl-Grassauer E; Grassauer A; Lion T; Mueller CA
    Respir Res; 2013 Nov; 14(1):124. PubMed ID: 24219370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold.
    Fazekas T; Eickhoff P; Pruckner N; Vollnhofer G; Fischmeister G; Diakos C; Rauch M; Verdianz M; Zoubek A; Gadner H; Lion T
    BMC Complement Altern Med; 2012 Sep; 12():147. PubMed ID: 22950667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold.
    Eccles R; Meier C; Jawad M; Weinmüllner R; Grassauer A; Prieschl-Grassauer E
    Respir Res; 2010 Aug; 11(1):108. PubMed ID: 20696083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial.
    Eccles R; Winther B; Johnston SL; Robinson P; Trampisch M; Koelsch S
    Respir Res; 2015 Oct; 16():121. PubMed ID: 26438038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data.
    Hemilä H; Chalker E
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00810. PubMed ID: 34128358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of iota-carrageenan nasal spray in treatment and prevention of the common cold.
    Bichiri D; Rente AR; Jesus Â
    Med Pharm Rep; 2021 Jan; 94(1):28-34. PubMed ID: 33629045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review.
    Frediansyah A
    Clin Epidemiol Glob Health; 2021; 12():100826. PubMed ID: 34222718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease.
    Figueroa JM; Lombardo ME; Dogliotti A; Flynn LP; Giugliano R; Simonelli G; Valentini R; Ramos A; Romano P; Marcote M; Michelini A; Salvado A; Sykora E; Kniz C; Kobelinsky M; Salzberg DM; Jerusalinsky D; Uchitel O
    Int J Gen Med; 2021; 14():6277-6286. PubMed ID: 34629893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Saliva of Probands Sucking an Iota-Carrageenan Containing Lozenge Inhibits Viral Binding and Replication of the Most Predominant Common Cold Viruses and SARS-CoV-2.
    Morokutti-Kurz M; Unger-Manhart N; Graf P; Rauch P; Kodnar J; Große M; Setz C; Savli M; Ehrenreich F; Grassauer A; Prieschl-Grassauer E; Schubert U
    Int J Gen Med; 2021; 14():5241-5249. PubMed ID: 34526804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a nasal spray containing xylometazoline hydrochloride and iota-carrageenan for the symptomatic relief of nasal congestion caused by rhinitis and sinusitis.
    Graf C; Bernkop-Schnürch A; Egyed A; Koller C; Prieschl-Grassauer E; Morokutti-Kurz M
    Int J Gen Med; 2018; 11():275-283. PubMed ID: 30013382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing upper respiratory tract infections with prophylactic nasal carrageenan: a feasibility study.
    Halley C; Honeywill C; Kang J; Pierse N; Robertson O; Rawlinson W; Stelzer-Braid S; Willink R; Crane J
    Future Microbiol; 2023 Dec; 18():1319-1328. PubMed ID: 37830932
    [No Abstract]   [Full Text] [Related]  

  • 13. Iota-Carrageenan is a potent inhibitor of rhinovirus infection.
    Grassauer A; Weinmuellner R; Meier C; Pretsch A; Prieschl-Grassauer E; Unger H
    Virol J; 2008 Sep; 5():107. PubMed ID: 18817582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heated, humidified air for the common cold.
    Singh M
    Cochrane Database Syst Rev; 2004; (2):CD001728. PubMed ID: 15106160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heated, humidified air for the common cold.
    Singh M
    Cochrane Database Syst Rev; 2001; (4):CD001728. PubMed ID: 11687118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of zinc nasal spray for the treatment of upper respiratory illness in adults.
    Belongia EA; Berg R; Liu K
    Am J Med; 2001 Aug; 111(2):103-8. PubMed ID: 11498062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Acyl Gellan as an Excipient to Improve the Sprayability and Mucoadhesion of Iota Carrageenan in a Nasal Spray to Prevent Infection With SARS-CoV-2.
    Robinson TE; Moakes RJA; Grover LM
    Front Med Technol; 2021; 3():687681. PubMed ID: 35047933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heated, humidified air for the common cold.
    Singh M
    Cochrane Database Syst Rev; 2000; (2):CD001728. PubMed ID: 10796659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of creating a non-specific, virus-hostile environment in the nasopharynx on symptoms and duration of common cold.
    Hull D; Rennie P; Noronha A; Poore C; Harrington N; Fearnley V; Passàli D
    Acta Otorhinolaryngol Ital; 2007 Apr; 27(2):73-7. PubMed ID: 17608134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections.
    Mukherjee PK; Esper F; Buchheit K; Arters K; Adkins I; Ghannoum MA; Salata RA
    BMC Infect Dis; 2017 Jan; 17(1):74. PubMed ID: 28088167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.